


PATENT
Docket No. 273012013101

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on December 11, 2003.


Diane Blevins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Janice NORTH et al.

Serial No.: 10/622,310

Filing Date: July 17, 2003

For: TREATMENT OF MACULAR EDEMA

Examiner: Unassigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/199,662, now U.S. Patent No. 6,599,891, filed July 19, 2002, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 273012013101. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 11, 2003

Respectfully submitted,

By: Karen R. Zachow
Karen R. Zachow
Reg. No. 46,332
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5191
Facsimile: (858) 720-5125



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 273012013101	Application Number 10/622,310
	Applicant NORTH et al.	
	Filing Date July 17, 2003	Group Art Unit 1614
	Mailing Date December 11, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	05/1998	5,756,541	Strong et al.	514	502	
	2.	08/1998	5,798,349	Levy et al.	514	185	
	3.	08/2001	6,270,749	Blumenkranz et al.	424	9.61	

Examiner Initials		Date	Document No.	Country	Class	Subclass	Translation YES NO
	4.	08/2002	WO 02/064163	WIPO			

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	5.	Aiello, L. M., et al., "Diabetic Retinopathy" Chapter 26 <i>In Retina-Vitreous-Macula: Diabetic Retinopathy</i> (Guyer et al., eds.) W.B. Saunders Co. pp.316-344 (1999).
	6.	Early Treatment Diabetic Retinopathy Study Research Group, "Photocoagulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report Number 1" Arch Ophthalmol 103:1796-1806 (1985).
	7.	Early Treatment Diabetic Retinopathy Study Research Group, "Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9" Ophthalmology 98:766-785 (1991).
	8.	Ferris, F. L. and Davis, M. D., "Treating 20/20 Eyes with Diabetic Macular Edema" Arch Ophthalmol 117(5):675-676 (1999).
	9.	Ferris, F. L. and Patz, A., "Macular Edema. A Complication of Diabetic Retinopathy" Surv Ophthalmol 28(Suppl):452-461 (1984).
	10.	Klein, R., et al., "The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XI. The Incidence of Macular Edema" Ophthalmology 96:1501-1510 (1989).

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 273012013101

Application Number 10/622,310

INFORMATION DISCLOSURE & TRADEXION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

NORTH et al.

Filing Date July 17, 2003

Group Art Unit 1614

Mailing Date December 11, 2003

- | | |
|-----|---|
| 11. | Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, "Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: One-Year Results of 2 Randomized Clinical Trials-TAP Report 1" Archives of Ophthalmology 117(10):1329-1345 (1999). |
| 12. | Boyer, D.S., et al., "Efficacy of Verteporfin Photodynamic Therapy on Laser Induced Choroidal Neovascularization and the Ancillary Effect on Diabetic Microvasculopathy" IOVS, Meeting Info: Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida, April 29-May 4, 2001 42(4):S695 (2001). |
| 13. | Lovestam-Adrian, M., et al., "Photocoagulation of Diabetic Macular Oedema: Complications and Visual Outcome" Acta Ophthalmologica Scandinavica 78(6):667-671 (2000). |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.